Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
出版年份 2013 全文链接
标题
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
作者
关键词
-
出版物
JOURNAL OF CLINICAL ONCOLOGY
Volume 31, Issue 19, Pages 2485-2492
出版商
American Society of Clinical Oncology (ASCO)
发表日期
2013-05-29
DOI
10.1200/jco.2012.45.5766
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Updates of mTOR Inhibitors
- (2012) Hongyu Zhou et al. Anti-Cancer Agents in Medicinal Chemistry
- ATP-Competitive Inhibitors of mTOR: An Update
- (2011) S. Schenone et al. CURRENT MEDICINAL CHEMISTRY
- Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
- (2011) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity of Ridaforolimus and Potential Cell-Cycle Determinants of Sensitivity in Sarcoma and Endometrial Cancer Models
- (2011) R. M. Squillace et al. MOLECULAR CANCER THERAPEUTICS
- Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens
- (2011) V. M. Rivera et al. MOLECULAR CANCER THERAPEUTICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) P. C. W. Hogendoorn et al. ANNALS OF ONCOLOGY
- Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) P. G. Casali et al. ANNALS OF ONCOLOGY
- Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
- (2009) S. Bielack et al. ANNALS OF ONCOLOGY
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
- (2009) C. M. Hartford et al. CLINICAL CANCER RESEARCH
- Enhancing mTOR-targeted cancer therapy
- (2009) Xuerong Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors
- (2009) Yoh Dobashi et al. MODERN PATHOLOGY
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis
- (2008) John J. Bissler et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started